


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:



LISTING OF CLAIMS:

1. (currently amended): A composition ~~comprising~~ consisting essentially of:
a thiazole derivative of the formula (I):




wherein

R^1 is acyl;


X is a bivalent residue selected from the group consisting of  and  and may be substituted;

Y is a bond, lower alkylene, lower alkenylene or $-CONH-$; and

Z is a group of the formula:



wherein R^2 is a group of the formula:




(wherein G is a bond, $-NHCOCH_2-$ or lower alkylene and R^4 is hydrogen, $-NH_2$ or lower alkyl);

or a pharmaceutically acceptable salt thereof,
water, and
an additive selected from the group consisting of polyol, sugar alcohol, boric acid and a salt of boric acid.

2. (canceled).

3. (previously presented): The composition of claim 1, wherein R² of the formula (I) is a group of the formula:



(wherein G is a bond, -NHCOCH₂- or lower alkylene and R⁴ is hydrogen or lower alkyl);
or a pharmaceutically acceptable salt thereof.

4. (previously presented): The composition of claim 1, wherein R¹ of the formula (I) is alkylcarbonyl and X is optionally substituted by methylsulfonylbenzyl, or a pharmaceutically acceptable salt thereof.

5. (previously presented): The composition of claim 1, wherein the thiazole derivative is
N-{4-[2-(4-{[amino(imino)methyl]amino}phenyl)ethyl]-1,3-thiazol-2-yl}acetamide,
N-{4-[2-(4-{[amino(imino)methyl]amino}phenyl)ethyl]-5-[4-(methylsulfonyl)benzyl]-
1,3-thiazol-2-yl}acetamide,

N-{4-[2-(4-{[hydrazino(imino)methyl]amino}phenyl)ethyl]-5-[4-(methylsulfonyl)benzyl]-1,3-thiazol-2-yl}acetamide,

N-{4-[2-(4-{[hydrazino(imino)methyl]amino}phenyl)ethyl]-1,3-thiazol-2-yl}acetamide,

or

N-(4-{2-[4-(2-{[amino(imino)methyl]amino}ethyl)phenyl]ethyl}-1,3-thiazol-2-yl)acetamide,

or a pharmaceutically acceptable salt thereof.

6. (previously presented): The composition of claim 1, wherein R¹ of the formula (I) is alkylcarbonyl and X is optionally substituted by methylsulfonylbenzyl, or a pharmaceutically acceptable salt thereof.


7. (previously presented): The composition of claim 3, wherein R¹ of the formula (I) is alkylcarbonyl and X is optionally substituted by methylsulfonylbenzyl, or a pharmaceutically acceptable salt thereof.

8. (previously presented): The composition of Claim 1, wherein the additive is glycerin.

9. (previously presented): The composition of Claim 1, wherein the additive is mannitol.



10. (previously presented): The composition of Claim 1, wherein the additive is boric acid or a salt of boric acid.

11. (new): A method for increasing solubility of a thiazole derivative of the following formula (I) in water, consisting essentially of preparing a composition consisting essentially of: a thiazole derivative of the formula (I):



wherein


R¹ is acyl;

X is a bivalent residue selected from the group consisting of  and 


and may be substituted;

Y is a bond, lower alkylene, lower alkenylene or -CONH-; and

Z is a group of the formula:



wherein R² is a group of the formula:




(wherein G is a bond, -NHCOCH₂- or lower alkylene and R⁴ is hydrogen, -NH₂ or lower alkyl);

or a pharmaceutically acceptable salt thereof,

water, and

an additive selected from the group consisting of polyol, sugar alcohol, boric acid and a salt of boric acid.

12. (new): The method of claim 11, wherein R² of the formula (I) is a group of the formula:



(wherein G is a bond, -NHCOCH₂- or lower alkylene and R⁴ is hydrogen or lower alkyl);

or a pharmaceutically acceptable salt thereof.

13. (new): The method of claim 11, wherein R^1 of the formula (I) is alkylcarbonyl and X is optionally substituted by methylsulfonylbenzyl, or a pharmaceutically acceptable salt thereof.

14. (new): The method of claim 11, wherein the thiazole derivative is
N-{4-[2-(4-{[amino(imino)methyl]amino}phenyl)ethyl]-1,3-thiazol-2-yl}acetamide,
N-{4-[2-(4-{[amino(imino)methyl]amino}phenyl)ethyl]-5-[4-(methylsulfonyl)benzyl]-
1,3-thiazol-2-yl}acetamide,
N-{4-[2-(4-{[hydrazino(imino)methyl]amino}phenyl)ethyl]-5-[4-(
(methylsulfonyl)benzyl)-1,3-thiazol-2-yl}acetamide,

N-{4-[2-(4-{[hydrazino(imino)methyl]amino}phenyl)ethyl]-1,3-thiazol-2-yl}acetamide,
or

N-(4-{2-[4-(2-{[amino(imino)methyl]amino}ethyl)phenyl]ethyl}-1,3-thiazol-2-
yl)acetamide,

or a pharmaceutically acceptable salt thereof.

15. (new): The method of claim 11, wherein R^1 of the formula (I) is alkylcarbonyl and X is optionally substituted by methylsulfonylbenzyl, or a pharmaceutically acceptable salt thereof.

16. (new): The method of claim 12, wherein R^1 of the formula (I) is alkylcarbonyl and X is optionally substituted by methylsulfonylbenzyl, or a pharmaceutically acceptable salt thereof.

17. (new): The method of Claim 11, wherein the additive is glycerin.

18. (new): The method of Claim 11, wherein the additive is mannitol.

19. (new): The method of Claim 11, wherein the additive is boric acid or a salt of boric acid.